

1 **Submitting to:** *PLOS Medicine*

2
3 **Characterizing Disparities in the HIV Care Continuum among Transgender and Cisgender**
4 **Medicare Beneficiaries**

5
6
7 *Jaclyn M.W. Hughto, PhD, MPH,¹⁻³
8 Hiren Varma, MS, MBA⁴⁻⁵ Kim Yee, MPH,⁶ Gray Babbs, MPH⁴⁻⁵
9 Landon D. Hughes, PhD⁷⁻⁸ David R. Pletta, PhD, MPH,² David J. Meyers, PhD, MPH,⁴⁻⁵
10 Theresa I. Shireman, PhD⁴⁻⁵

11
12
13 ¹ Departments of Behavioral and Social Sciences and Epidemiology, Brown University School of
14 Public Health, Providence, RI, United States

15
16 ² Center for Health Promotion and Health Equity, Brown University School of Public Health,
17 Providence, RI, United States

18
19 ³ The Fenway Institute, Fenway Health, Boston, MA, United States

20
21 ⁴ Center for Gerontology & Healthcare Research, Brown University School of Public Health,
22 Providence, RI, United States

23
24 ⁵ Department of Health Services Policy & Practice, Brown University School of Public Health,
25 Providence, RI, United States

26
27 ⁶ OHSU-PSU School of Public Health, Portland, OR, United States

28
29 ⁷ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United
30 States

31
32 ⁸ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care
33 Institute, Boston, MA, United States

34
35
36
37 *** Corresponding Author:**

38
39 Jaclyn M.W. Hughto, PhD, MPH
40 Brown University School of Public Health
41 Center for Health Promotion and Health Equity
42 121 South Main Street
43 Providence, RI 02903, United States
44 jaclyn_hughto@brown.edu
45 Phone: 401-863-6580

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

ABSTRACT

Background: In the US, transgender and gender-diverse (TGD) individuals, particularly trans feminine individuals, experience a disproportionately high burden of HIV relative to their cisgender counterparts. While engagement in the HIV Care Continuum (e.g., HIV care visits, antiretroviral (ART) prescribed, ART adherence) is essential to reduce viral load, HIV transmission, and related morbidity, the extent to which TGD people engage in one or more steps of the HIV Care Continuum at similar levels as cisgender people is understudied on a national level and by gendered subgroups.

Methods and Findings: We used Medicare Fee-for-Service claims data from 2009 to 2017 to identify TGD (trans feminine and non-binary (TFN), trans masculine and non-binary (TMN), unclassified gender) and cisgender (male, female) beneficiaries with HIV. Using a retrospective cross-sectional design, we explored within- and between-gender group differences in the predicted probability (PP) of engaging in one or more steps of the HIV Care Continuum. TGD individuals had a higher predicted probability of every HIV Care Continuum outcome compared to cisgender individuals [HIV Care Visits: TGD PP=0.22, 95% Confidence Intervals (CI)=0.22-0.24; cisgender PP=0.21, 95% CI=0.21-0.22); Sexually Transmitted Infection (STI) Screening (TGD PP=0.12, 95% CI=0.11-0.12; cisgender PP=0.09, 95% CI=0.09-0.10); ART Prescribed (TGD PP=0.61, 95% CI=0.59-0.63; cisgender PP=0.52, 95% CI=0.52-0.54); and ART Persistence or adherence (90% persistence: TGD PP=0.27, 95% CI=0.25-0.28; 95% persistence: TGD PP=0.13, 95% CI=0.12-0.14; 90% persistence: cisgender PP=0.23, 95% CI=0.22-0.23; 95% persistence: cisgender PP=0.11, 95% CI=0.11-0.12)]. Notably, TFN individuals had the highest probability of every outcome (HIV Care Visits PP =0.25, 95% CI=0.24-0.27; STI Screening PP =0.22, 95% CI=0.21-0.24; ART Prescribed PP=0.71, 95% CI=0.69-0.74; 90%

69 ART Persistence PP=0.30, 95% CI=0.28-0.32; 95% ART Persistence PP=0.15, 95% CI=0.14-
70 0.16) and TMN people or cisgender females had the lowest probability of every outcome (HIV
71 Care Visits: TMN PP =0.18, 95% CI=0.14-0.22; STI Screening: Cisgender Female PP =0.11,
72 95% CI=0.11-0.12; ART Receipt: Cisgender Female PP=0.40, 95% CI=0.39-0.42; 90% ART
73 Persistence: TMN PP=0.15, 95% CI=0.11-0.20; 95% ART Persistence: TMN PP=0.07, 95%
74 CI=0.04-0.10). The main limitation of this research is that TGD and cisgender beneficiaries were
75 included based on their observed care, whereas individuals who did not access relevant care
76 through Fee-for-Service Medicare at any point during the study period were not included. Thus,
77 our findings may not be generalizable to all TGD and cisgender individuals with HIV, including
78 those with Medicare Advantage or other types of insurance.

79 Conclusions. Although TGD beneficiaries living with HIV had superior engagement in
80 the HIV Care Continuum than cisgender individuals, findings highlight notable disparities in
81 engagement for TMN individuals and cisgender females, and engagement was still low for all
82 Medicare beneficiaries, independent of gender. Interventions are needed to reduce barriers to
83 HIV care engagement for all Medicare beneficiaries to improve treatment outcomes and reduce
84 HIV-related morbidity and mortality in the US.

85

86

87 **INTRODUCTION**

88 Transgender and gender diverse (TGD) people in the United States (US) are at
89 heightened risk for HIV relative to cisgender (non-transgender) people, with much of the burden
90 experienced by trans feminine people [1-5]. Indeed, a recent analysis of Medicare data found that
91 trans feminine and non-binary (TFN) people had 9 and 4.5 times the probability of having HIV
92 compared to cisgender males and cisgender females or trans masculine and non-binary (TMN)
93 people, respectively [5]. These disparities stem from multilevel sources of stigma that lead to
94 social and economic marginalization, limited access to preventative healthcare, poor mental
95 health, and coping behaviors that can increase the risk of HIV transmission, including injection
96 drug use and sex work [1, 6-9].

97 The HIV Care Continuum characterizes the HIV care services and outcomes that are
98 essential for reducing HIV-related morbidity, mortality, and forward transmission [10]. These
99 essential health services include linkage and retention in care, as well as uptake and adherence to
100 antiretroviral therapy (ART) to achieve viral suppression [10, 11]. Prior research has documented
101 lower engagement in one or more stages of the HIV care continuum for TGD people, with
102 several studies finding that TFN people have suboptimal ART uptake [12, 13], ART adherence
103 [13-16], and viral suppression [13, 15, 17, 18].

104 The few studies that have examined differences between TGD people overall relative to
105 cisgender people have found conflicting results. Indeed, one study found that TGD people were
106 less likely than cisgender men and women to be retained in care and achieve viral suppression
107 [18], whereas another study found that TGD people had comparable retention in care as
108 cisgender men, higher ART use than both cisgender men and women, and comparable level of
109 HIV suppression relative to cisgender men and women [19]. Notably, none of these studies

110 comparing TGD people to cisgender people [12-16, 18, 19] explored HIV Care Continuum
111 outcomes among trans masculine and non-binary (TMN) people independent of TFN people,
112 which limits our understanding of important within and between group gender differences. To
113 have a complete understanding of which groups may face barriers to HIV Care Continuum
114 engagement and warrant tailored interventions, national research is needed to explore HIV care
115 engagement among TGD subgroups as well as relative to their cisgender counterparts.

116 Much of the existing research exploring HIV Care Continuum engagement among TGD
117 people also fails to consider the impact of insurance coverage. This is a critical gap in the
118 literature, given that HIV care quality, satisfaction, and related health outcomes have been shown
119 to differ for members of the general population with and without health insurance [20-23].
120 Moreover, national survey research finds that 86% of US TGD adults are insured [24] and
121 Medicare insures more than a quarter of people living with HIV/AIDS [5]. Because health
122 insurance is essential to ensuring that people living with HIV can afford the care needed to
123 reduce HIV-related morbidity and mortality [25], understanding TGD and cisgender Medicare
124 beneficiaries' engagement in the HIV Care Continuum overall and by gender subgroup can
125 identify the subpopulations in greatest need of interventions to optimize HIV care access, use,
126 and delivery.

127 Building on prior research [5, 26-31], we adapted and applied claims-based methods to
128 achieve the following objectives: [1] identify TGD and cisgender Medicare beneficiaries with
129 HIV and stratify the samples by gender, and [2] explore within- and between-group gender
130 differences in HIV Care Continuum engagement. Findings from this national study can enable a
131 better understanding of HIV Care Continuum engagement among Medicare beneficiaries who
132 are engaged in some level of care, with the goal of identifying the TGD and cisgender subgroups

133 who have the greatest need of tailored interventions to optimize HIV clinical care delivery and
134 improve HIV-related outcomes.

135 **METHODS**

136 Study Design/Data Source

137 We conducted a retrospective cross-sectional analysis to identify US TGD and cisgender
138 Medicare beneficiaries (aged ≥ 18 years) with HIV and stratify these groups by inferred gender.
139 Fee-for-Service Medicare data were accessed through the Virtual Data Resource Center
140 maintained by the Centers for Medicare & Medicaid Services (CMS). We queried the Medicare
141 Master Beneficiary Summary File and final paid claims for inpatient, physician, and other
142 suppliers, and prescription services from 2008 to 2017. The study was considered exempt by the
143 Brown University Institutional Review Board.

144 Identifying TGD Individuals and Stratifying by Gender

145 To identify TGD individuals, we applied an algorithm that was originally developed with
146 commercial insurance claims data [31] and later adapted for Medicare [5]. These methods and
147 the corresponding codes used to identify the TGD sample are described elsewhere [26, 31].
148 Briefly, we included any person with a TGD-related diagnosis (e.g., “gender identity disorder”);
149 TGD-conclusive procedures (e.g., “operations for sex transformation, not elsewhere classified”);
150 or a diagnosis of “endocrine disorder not otherwise specified” in conjunction with a transgender-
151 suggestive procedure or gender-affirming hormone prescription.

152 We subsequently applied a stepwise approach [31] to categorize the inferred gender of
153 the TGD sample. As described in detail elsewhere [5], briefly, we first classified the inferred
154 gender of TGD individuals based on the presence of claims for gender-affirming genital
155 surgeries (e.g., “vaginal construction,” “construction of penis”). Then, within the remaining

156 sample, we categorized the sample by gender if they had certain types of highly specific and
157 highly sensitive reproductive anatomy-specific care and diagnoses (e.g., hysterectomy,
158 pregnancy, prostate cyst, prostate screening). Next, we categorized individuals according to their
159 receipt of gender-affirming hormones or procedures. Finally, using the remaining sample,
160 individuals who had other reproductive anatomy-related diagnoses or procedures (e.g.,
161 vulvectomy, testicular hyperfunction) were categorized by inferred gender. These two groups
162 were classified as TMN or TFN. Individuals who had not yet been assigned a gender category or
163 those with conflicting codes at the final step remained unclassified. The unclassified group was
164 comprised of people with a transgender-related diagnosis code and no gender-affirming
165 hormones or procedures or reproductive-anatomy-related care or who had conflicting codes.

166 Identifying Cisgender Comparison Group

167 After identifying the TGD cohort, we selected a random 5% sample from the remaining
168 Medicare beneficiaries, henceforth considered the cisgender sample. The sex of the beneficiaries
169 classified as cisgender was determined from the Master Beneficiary Summary File. Because
170 identification of the TGD cohort relied on engagement in care, we limited the cisgender cohort to
171 beneficiaries who had at least one Part A or B claim and one Part D claim between 2008 and
172 2017. We also excluded cisgender beneficiaries with missing data on sex and/or date of birth
173 (about 5% of the random sample).

174 Identifying Individuals with HIV

175 We updated an algorithm developed for Medicaid data prior to 2016 and adapted it to
176 identify Medicare beneficiaries with HIV between 2008 and 2017 [29, 30]. First, we used ICD-9
177 and ICD-10 codes to identify individuals who had an HIV diagnosis code in any claim field (e.g.,
178 ICD-9: 043.0 – HIV Disease). Those with a diagnosis code on one or more inpatient or long-term

179 care claims or on two or more claims from an outpatient carrier file were considered to have
180 HIV. Individuals who only had a qualifying diagnosis on one claim from an outpatient carrier
181 file were additionally required to have procedure codes for two or more CD4 count tests, two or
182 more viral load tests, or at least one ART prescription to be considered to have HIV. We
183 identified 1,515 TGD individuals and 11,001 cisgender individuals using HIV diagnosis codes
184 (Electronic Supplement Fig 1 and Fig 2). Next, we identified individuals who were prescribed
185 ART but did not have an HIV diagnosis code documented during the study period. For
186 individuals without an HIV diagnosis, they were first required to have prescriptions for two or
187 more ART ingredients. To ensure that we did not include individuals who were taking
188 antiretroviral medication for HIV prevention (i.e., Pre-Exposure Prophylaxis), we required
189 individuals with no HIV diagnosis and prescriptions for two or more ART ingredients to have
190 diagnostic codes for an HIV-related opportunistic infection (e.g., ICD-10: C46.0-9 - Kaposi
191 Sarcoma), an HIV-related wasting or dementia condition (e.g., ICD-9: 348.3, Encephalopathy,
192 unspecified; ICD-10: R64 - Wasting Syndrome (Cachexia)), or two or more viral load tests or
193 CD4 count tests. The ART pathway identified an additional 303 TGD individuals and 2,220
194 cisgender individuals (Electronic Supplement Fig 1 and Fig 2). Finally, we identified individuals
195 who were categorized as having HIV within the Chronic Condition Warehouse File and were not
196 captured via the other two pathways (TGD n=253; cisgender n=4,222). Together, these
197 approaches yielded an initial sample of 2,071 TGD and 17,443 cisgender Medicare beneficiaries
198 with HIV. Relatively similar proportions of TGD and cisgender samples were identified within
199 the respective methods, with a modestly higher proportion of TGD people identified using the
200 HIV diagnosis method and a higher proportion of cisgender people identified using Chronic
201 Condition Warehouse indicators (Electronic Supplement Fig 1 and Fig 2).

202 Measures

203 *Sociodemographics.* Age was categorized as 18-24, 25-34, 35-44, 45-54, and 55+ years.
204 These age categories were used because only 10% of the TGD sample with HIV were age 55
205 years and older at enrollment, and sample sizes for some TGD subgroups (i.e., TMN in the oldest
206 age category) would be too small to report if we split the age categories at 65+. Race and
207 ethnicity were categorized as White (non-Hispanic), Black (non-Hispanic), Hispanic, or Another
208 race and ethnicity (non-Hispanic). Due to small cell sizes that cannot be reported according to
209 our Medicare data use agreement, we combined Asian or Pacific Islander, American Indian or
210 Alaska Native, and other (race or ethnicity) [32]. US Census regions included Northeast,
211 Midwest, South, West, and Unknown.

212 *HIV Care Continuum.* We explored 5 HIV Care Continuum outcomes: HIV care visit
213 engagement, sexually transmitted infections (STI) screening, ART receipt, 90% ART
214 persistence, and 95% ART persistence. For all measures and for each performance period (i.e.,
215 calendar year), we excluded individuals with fewer than 6 months of continuous Fee-for-Service
216 coverage or who died during the performance period. All measures were assessed after the date
217 that an individual was initially identified as having HIV.

218 To assess HIV Care Visit engagement, we adapted a CMS measure to assess the quality
219 of services provided for the primary management of patients with HIV/AIDS [33] for
220 retrospective measurement with Medicare claims data. Specifically, HIV Care Visit engagement
221 was operationalized as the percentage of adult beneficiaries with HIV who had at least two HIV-
222 related medical visits in a calendar year, with a minimum of 60 days between medical visits.

223 To assess STI Screening engagement, we adapted a CMS measure to assess the quality of
224 services provided for the primary management of patients with HIV/AIDS [34] for retrospective

225 measurement with Medicare claims data. Specifically, STI testing was operationalized as the
226 percentage of adult beneficiaries with HIV who received chlamydia, gonorrhea, and syphilis
227 screenings at least once per calendar year.

228 Prescribed ART outcome was operationalized as the percentage of adult beneficiaries
229 with HIV who had at least one day of the 3-drug ART regimen in a calendar year [29, 30].

230 The 90% ART Persistence outcome was operationalized as having at least 90%
231 proportion of days covered (PDC) in a calendar year. We generated a day-by-day array of
232 estimated exposure using the record dates of fills/refills and days supplied for each ART
233 prescription. The PDC corresponds to the proportion of days that a person possessed medication
234 within a defined window of observation and is the Pharmacy Quality Alliance's preferred
235 method for measuring ART persistence (a proxy for adherence) via claims data [35, 36]. The
236 PDC metric accounts for potential gaps (e.g., hospitalizations) as well as overlapping days for
237 early refills [37]. An individual was considered persistent to ART if their PDC for a 3-drug ART
238 regimen was 90% or greater in any calendar year [38]. Although 95% has historically been
239 considered the gold standard of adherence to ART [39], as of 2019, the Pharmacy Quality
240 Alliance set adherence to $\geq 90\%$ [36].

241 The 95% ART Persistence outcome was also assessed since guidelines for a lower
242 adherence threshold were set after the last year of the study period [36]. Individuals were
243 considered to have 95% ART persistence if their PDC for a 3-drug ART regimen was 95% or
244 greater in any calendar year.

245 Analytic Sample

246 Using beneficiaries' date of birth at enrollment, we restricted the sample to individuals
247 who were age 18 years or older at enrollment, who were alive for at least 12 months of a single

248 performance period/year, and who had continuous enrollment in Fee-for-Service coverage for at
249 least six months during one or more performance year/period, resulting in a final analytic sample
250 of 12,779 adult Medicare beneficiaries with HIV, of which 1,678 were TGD and 10,681 were
251 cisgender.

252 Data Analysis

253 All analyses were descriptive. We report the demographic characteristics of the TGD and
254 cisgender samples at enrollment, reporting the raw sample size and frequency overall and by
255 gender subgroup. Since the distribution of sociodemographic characteristics varied by gender
256 subgroup (TFN vs. TMN, cisgender male vs. cisgender female), we calculated the predicted
257 probability of each condition while controlling for age at enrollment. To facilitate within- and
258 between-group comparisons, we obtained the predicted probabilities of each HIV Care
259 Continuum outcome by gender subgroups (TFN, TMN, Unclassified [within the TGD cohort],
260 cisgender males, cisgender females), holding age and gender category at their means. All
261 analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). Notably, the small sample
262 sizes of some TGD subgroups limited our ability to control for other variables.

263 **RESULTS**

264 Demographic Characteristics

265 Table 1 summarizes the demographic characteristics of the sample. Of the 1,678 TGD
266 beneficiaries with HIV in our sample, 62.7% (n=1,053) were categorized as TFN, 10.1%
267 (n=169) as TMN, and the gender could not be inferred and classified for 27.2% (n=456). Of the
268 10,681 cisgender individuals with HIV in the comparison group 66.9% (n=7,143) were male, and
269 33.12% (n= 3,538) were female.

270 Overall, a higher proportion of TGD beneficiaries with HIV were under age 55 (90.0%
271 TGD; 65.3% cisgender), which can be attributed to the fact that 93.4% of the TGD sample was
272 eligible for Medicare due to disability rather than age, compared to 75.1% of the cisgender
273 sample. Additionally, 62.6% of the TGD sample and 53.6% of the cisgender sample were Black
274 or Hispanic. The largest percentage of beneficiaries for both the TGD (39.8%) and cisgender
275 (43.5%) samples lived in the South at enrollment. The average months of enrollment in Fee-for-
276 Service were also fairly comparable across groups (TGD mean=87.4, Standard Deviation
277 (SD)=32.2; cisgender mean=84.67, SD=35.0).

278 HIV Care Continuum

279 Fig 1 presents results from the age-adjusted models for each HIV Care Continuum
280 outcome for the TGD and cisgender samples and gender subgroups (TMN, TFN, Unclassified,
281 cisgender males, cisgender females). Results from unadjusted models and the exact values from
282 the adjusted model are presented in the Electronic Supplement Tables 1 and 2, respectively.

283 Once diagnosed with HIV, TGD and cisgender Medicare beneficiaries had a similar
284 predicted probability (PP; herein referred to as “probability) of attending two or more HIV care
285 visits in a given year over the study period (TGD PP=0.22, 95% Confidence Interval (CI)=0.22-
286 0.24; cisgender PP=0.21, 95% CI=0.21-0.22). Moreover, the probability of this outcome was
287 similar across gender subgroups (TFN PP=0.25, 95% CI=0.24-0.27; TMN PP=0.18, 95%
288 CI=0.14-0.22; unclassified PP=0.22, 95% CI=0.20-0.25; cisgender males PP=0.22, 95%
289 CI=0.22-0.23; cisgender females PP=0.21, 95% CI=0.20-0.22).

290 There were slightly larger differences in the probability of being screened for STIs (i.e.,
291 chlamydia, gonorrhea, and syphilis) annually over the study period, with TGD beneficiaries with
292 HIV having a higher probability (PP=0.12, 95% CI=0.11-0.12) compared to cisgender (PP=0.09,

293 95% CI=0.09-0.10). The probability of annual STI testing was substantially higher among TFN
294 people (PP=0.22, 95% CI=0.21-0.24) relative to all other groups (TMN PP=0.14, 95% CI=0.10-
295 0.18; unclassified PP=0.15, 95% CI=0.13-0.17; cisgender males PP=0.16, 95% CI=0.15-0.17;
296 cisgender females PP=0.11, 95% CI=0.11-0.12).

297 For receipt of a 3-drug regimen of ART for at least one day in a calendar year, TGD
298 Medicare beneficiaries with HIV had a higher probability of the outcome (PP=0.61, 95%
299 CI=0.59-0.63) compared to cisgender beneficiaries (PP=0.52, 95% CI=0.52-0.54). This
300 difference is largely driven by the fact that the TFN and the gender unclassified group had a
301 much higher probability of this outcome (TFN PP=0.71, 95% CI=0.69-0.74; unclassified
302 PP=0.68, 95% CI=0.64-0.71).

303 Ninety percent ART persistence among those prescribed a 3-drug ART regimen were less
304 than half of the probabilities estimated for receipt among TGD (PP=0.27, 95% CI=0.25-0.28)
305 and cisgender people (PP=0.23, 95% CI=0.22-0.23). Further, the probability of 95% persistence
306 was about half the probability for 90% persistence (TGD PP=0.13, 95% CI=0.12-0.14; cisgender
307 PP=0.11, 95% CI=0.11-0.12). For both the 90% and 95% ART persistence outcomes, the
308 probability was meaningfully and significantly highest among TFN people (90% ART
309 Persistence: PP=0.30, 95% CI=0.28-0.32; 95% ART Persistence: PP=0.15, 95% CI=0.14-0.16).

310 **DISCUSSION**

311 To our knowledge, this is the first national, population-based analysis comparing HIV
312 Care Continuum engagement of TGD and cisgender Medicare beneficiaries with HIV. TGD
313 individuals had a nearly equal or slightly higher predicted probability of every HIV Care
314 Continuum outcome relative to cisgender individuals – a finding that aligns with one prior study
315 showing largely comparable HIV care engagement levels among TGD and cisgender patients

316 initiating care at an HIV clinic [30]. The subgroup differences were more variable, with TFN
317 individuals showing the highest probability of HIV care visit engagement, STI screening,
318 receiving ART, and ART persistence relative to all other groups, which is in opposition to prior
319 studies with individuals of varying or unknown insurance coverage that found lower engagement
320 in one or more stage of the HIV Care Continuum among TFN people relative to cisgender people
321 [12-16]. Further, with the exception of the STI testing, cisgender females and TMN people had a
322 slightly lower probability of engaging in the HIV Care Continuum than TFN people and
323 cisgender males – a finding that extends recent research that showed lower levels of ART
324 adherence among female vs. male Medicare beneficiaries [40]. These findings represent a novel
325 contribution to the field, given that HIV Care Continuum research has not historically included
326 TMN people or reported outcomes for this population separately from TFN people. Despite
327 documented gender differences, it is important to note that HIV care engagement was still low
328 regardless of gender, suggesting potential barriers to HIV care for all Medicare enrollees.

329 Findings provide insights into the TGD and cisgender groups that could benefit from
330 greater engagement in one or more steps of the HIV Care Continuum. We found comparable
331 probabilities of attending two or more HIV care visits in a calendar year across groups but an
332 elevated probability of being screened for STIs according to HIV quality care guidelines [33, 34]
333 among TGD beneficiaries relative to cisgender beneficiaries. The comparable probability of HIV
334 care visit engagement suggests that regardless of gender, Medicare beneficiaries with HIV are
335 being referred to and/or engaging in HIV care appointments at similar rates, though all groups
336 had low levels of engagement, suggesting barriers to HIV care access and utilization.
337 Conversely, when exploring STI screening, TFN people had the highest probability of meeting
338 the quality care performance measure, followed by TMN individuals. Since TGD people who are

339 on hormones are required to receive lab tests annually [41], it is possible that providers added on
340 STI screening when monitoring hormones. To that end, one recent study found gender-affirming
341 hormone therapy to be associated with a 25% increase in TGD adult patients' odds of screening
342 for chlamydia and gonorrhea [42]. Future qualitative work with patients and providers is needed
343 to better understand these mechanisms.

344 We found that TGD beneficiaries were more likely to be prescribed ART in a calendar
345 year than cisgender beneficiaries. Further, we found TGD beneficiaries were more likely to be
346 adherent (or persistent) to ART than cisgender beneficiaries, though 90% and 95% ART
347 persistence were low across all gender groups in alignment with prior research among the
348 general population of Medicare beneficiaries with HIV [40]. Previous work has found mixed
349 results regarding TGD people's likelihood of ART receipt or any ART use. Some studies found
350 no differences in ART prescription receipt among TFN people compared to other people with
351 HIV [15]. Other studies have found that TGD populations are less likely to receive any ART
352 than cisgender people living with HIV [13]. In contrast, results from studies comparing ART
353 adherence between TGD and cisgender populations have been more consistent. In studies using
354 convenience samples and multi-center cohorts, TGD people have been less likely to be adherent
355 to ART than cisgender people [13-15, 43]. TGD people with HIV have been shown to face
356 barriers to ART adherence, with studies finding that low levels of social support [13], housing
357 instability, and sex work are associated with lower adherence for some TGD populations [44].
358 Although it is likely that TGD Medicare beneficiaries with HIV in our sample face similar
359 barriers as those with and without insurance who were recruited from HIV clinics and other
360 community sites, it is possible that older and disabled cisgender Medicare beneficiaries face

361 unique barriers to ART adherence [40], thus contributing to suboptimal ART adherence for all
362 people with HIV in our sample.

363 We utilized claims data from a population insured by Medicare to investigate HIV Care
364 Continuum engagement outcomes, and our findings meaningfully add to knowledge about health
365 insurance and quality care among TGD people living with HIV in the US. To date, many of the
366 studies on US TGD people's ART use have had limited sample sizes and have not controlled for
367 insurance status [45, 46]. Considering insurance status is critical in light of emerging research
368 showing ART utilization in over 90% of TGD women with HIV living in Canada, a country with
369 universal health coverage [47]. Furthermore, health insurance coverage for gender-affirming
370 hormones may have downstream effects on access to and utilization of ART. In two recent
371 studies, TGD women receiving gender-affirming hormones had higher rates of care retention,
372 ART prescription, and adherence than TGD women not receiving hormones [48, 49]. Further,
373 compared to the general population, TGD people are less likely to have health insurance [50, 51],
374 which may decrease their access to HIV care engagement directly through cost barriers and
375 indirectly through missed linkages with primary and gender-affirming care.

376 To our knowledge, our study is the first to use Medicare claims data to compare ART
377 prescription and persistence between TGD and cisgender populations. Our study provides
378 fundamental baseline estimates on within- and between-group differences in HIV Care
379 Continuum engagement among a publicly insured adult population. We found evidence of
380 meaningfully higher STI screening and ART persistence within TFN people. Our results support
381 the need for ongoing mixed-methods research to identify the barriers to ART use and persistence
382 for groups with lower levels of utilization (e.g., TMN people and cisgender women) so that
383 tailored interventions can be developed.

384 *Limitations*

385 The study has limitations. First, since TGD beneficiaries were included in our study
386 based on their observed care, we are unable to validate whether the individuals we identified as
387 TGD were truly so or whether we inaccurately characterized individuals as cisgender based on
388 their absence of qualifying care. However, a similar claims-based algorithm has been found to
389 have high sensitivity and specificity [52], increasing our confidence in our approach. Second,
390 since our data did not capture gender identity, we were forced to infer the gender of our sample
391 and combine individuals who likely hold non-binary and binary gender identities in the same
392 category based on their shared use of certain gender-affirming hormones, procedures, or
393 anatomy-specific care. Non-binary TGD people have been shown to have differential healthcare
394 utilization and risks of various health outcomes than TFN or TMN people [53, 54], and
395 combining these groups may have obscured key differences in healthcare utilization. Third, our
396 algorithm to categorize the gender of TGD people relies on receipt of anatomy-specific or
397 gender-affirming care, so TGD people who did not have claims for this care during the study
398 period or had conflicting claims could not be classified as TFN or TMN. Although the
399 unclassified sample in this study and our prior work [5, 26] have a similar probability of
400 healthcare engagement and chronic conditions (including HIV) as TFN people, it is not possible
401 to discern which gender subgroups comprise this group. Fourth, both TGD and cisgender
402 beneficiaries were included in our study based on their observed care, whereas individuals who
403 did not access relevant care through Fee-for-Service Medicare at any point during the study
404 period were not included. Thus, our sample is unlikely to represent all TGD and cisgender
405 Medicare beneficiaries with HIV. Fifth, our data source did not contain information on important
406 sociodemographic characteristics, such as housing security and income, which may confound the

407 relationship between gender identity and our outcomes. Despite these limitations, our findings
408 provide important new insights into the HIV care received by TGD and cisgender Medicare
409 beneficiaries and serve as a signal for future research and intervention efforts.

410 Conclusion

411 We adapted prior algorithms [5, 26, 29-31] and HIV quality care guidelines [33, 34] to
412 identify a large sample of TGD and cisgender Medicare beneficiaries with HIV and examined
413 within- and between-group differences in HIV Care Continuum engagement among these
414 populations. Our novel methods to identify Medicare beneficiaries with HIV and explore HIV
415 Care Continuum engagement may be helpful for future researchers seeking to study HIV-related
416 outcomes among TGD and cisgender people using claims data. This study also advances HIV
417 health disparities research with TGD and cisgender people [12-16] by documenting within and
418 between group gender differences among TFN, TMN, cisgender male, and cisgender female
419 Medicare beneficiaries with HIV. While our findings regarding TFN people's engagement
420 differed from some prior studies that did not report insurance status [13, 14, 16] or included
421 uninsured or underinsured people [12, 15], we observed that TGD Medicare beneficiaries had a
422 higher probability of HIV Care Continuum engagement relative to cisgender beneficiaries with
423 HIV, with the highest engagement among TFN people. Although there is a need to increase HIV
424 Care Continuum engagement for all groups to better align with care guidelines, additional
425 mixed-methods research is needed to explore the mechanisms underlying the lower STI
426 screening and ART use documented among TMN people and cisgender females in this sample so
427 that provider and patient-level interventions can be developed to increase engagement and
428 ultimately reduce HIV-related morbidity and mortality among all people living with HIV.
429

430

FUNDING

431 This work is supported by: This work was supported by a Brown University Catalyst Award
432 (JWH & TIS: GR200019) and the National Institutes of Health (DJM & JWH: R01AG073440).
433 Data access was provided through a Health Equity Research Award (JWH & TIS) provided by
434 the Centers for Medicare & Medicaid Services. JWH's contribution was also supported in part by
435 the National Institute of Minority Health and Disparities (L60MD012898). LDH was supported
436 by the Rackham Merit Fellowship, the National Institute on Aging (T32AG000221). The funders
437 did not play any role in the study design, data collection and analysis, decision to publish, or
438 preparation of the manuscript.

439

440

REFERENCES

- 441 1. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al.
442 Estimating HIV prevalence and risk behaviors of transgender persons in the United States: A
443 systematic review. *AIDS and Behavior*. 2008;12(1):1-17.
- 444 2. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of
445 HIV and sexual behaviors among the US transgender population: A systematic review and meta-
446 analysis, 2006–2017. *American Journal of Public Health*. 2019;109(1):e1-e8.
- 447 3. Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, et al. Behavioral and
448 clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring
449 Project, United States, 2009. *Morbidity and Mortality Weekly Report: Surveillance Summaries*.
450 2014;63(5):1-28.
- 451 4. CDC. Estimated HIV incidence and prevalence in the United States, 2010–2015. HIV
452 Surveillance Supplemental Report 2018; 23 (No. 1). Centers for Disease Control and Prevention;
453 2018.
- 454 5. Hughto JMW, Varma H, Babbs G, Yee K, Alpert A, Hughes L, et al. Disparities in health
455 condition diagnoses among aging transgender and cisgender Medicare beneficiaries, 2008-2017.
456 *Frontiers in Endocrinology*. 2023;14.

- 457 6. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: A critical
458 review of stigma determinants, mechanisms, and interventions. *Social Science & Medicine*.
459 2015;147:222–31.
- 460 7. Hayes BK, Shanker A. MMWR Supplement on National HIV Behavioral Surveillance
461 Among Transgender Women-Seven Urban Areas, United States, 2019-2020. *Public Health*
462 *Reports*. 2024:333549241231190.
- 463 8. Clements-Nolle K, Marx R, Guzman R, Katz M. HIV prevalence, risk behaviors, health
464 care use, and mental health status of transgender persons: implications for public health
465 intervention. *American Journal of Public Health*. 2001;91(6):915.
- 466 9. Sevelius JM. Gender affirmation: A framework for conceptualizing risk behavior among
467 transgender women of color. *Sex Roles*. 2013;68(11-12):675-89.
- 468 10. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum:
469 updates, goals, and recommendations for the future. *AIDS Research and Therapy*. 2016;13(1):1-
470 7.
- 471 11. Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital
472 Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011.
473 *Morbidity and Mortality Weekly Report*. 2014;63(47):1113-7.
- 474 12. Melendez RM, Exner TA, Ehrhardt AA, Dodge B, Remien RH, Rotheram-Borus M-J, et
475 al. Health and health care among male-to-female transgender persons who are HIV positive.
476 *American Journal of Public Health*. 2006;96(6):1034-7.
- 477 13. Kalichman SC, Hernandez D, Finneran S, Price D, Driver R. Transgender women and
478 HIV-related health disparities: Falling off the HIV treatment cascade. *Sexual Health*.
479 2017;14(5):469-76.
- 480 14. Sevelius JM, Carrico A, Johnson MO. Antiretroviral therapy adherence among
481 transgender women living with HIV. *Journal of the Association of Nurses in AIDS Care*.
482 2010;21(3):256-64.
- 483 15. Mizuno Y, Frazier EL, Huang P, Skarbinski J. Characteristics of TG women living with
484 HIV receiving medical care in the United States. *LGBT Health*. 2015;2(3):228-34.

- 485 16. Dowshen N, Matone M, Luan X, Lee S, Belzer M, Fernandez MI, et al. Behavioral and
486 health outcomes for HIV+ young transgender women linked to and engaged in medical care.
487 *LGBT Health*. 2016;3(2):162-7.
- 488 17. Wiewel EW, Torian LV, Merchant P, Braunstein SL, Shepard CW. HIV diagnoses and
489 care among transgender persons and comparison with men who have sex with men: New York
490 City, 2006–2011. *American Journal of Public Health*. 2016;106(3):497-502.
- 491 18. Doshi RK, Milberg J, Isenberg D, Matthews T, Malitz F, Matosky M, et al. High rates of
492 retention and viral suppression in the US HIV safety net system: HIV care continuum in the
493 Ryan White HIV/AIDS Program, 2011. *Clinical Infectious Diseases*. 2014;60(1):117-25.
- 494 19. Yehia BR, Fleishman JA, Moore RD, Gebo KA. Retention in care and health outcomes
495 of transgender persons living with HIV. *Clinical Infectious Diseases*. 2013;57(5):774-6.
- 496 20. Katz MH, Marx R, Douglas JMJ, Bolan GA, Park M-S, Gurley RJ, et al. Insurance type
497 and satisfaction with medical care among HIV-infected men. *JAIDS Journal of Acquired
498 Immune Deficiency Syndromes*. 1997;14(1):35-43.
- 499 21. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al.
500 Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and
501 Services Utilization Study. *JAMA*. 1999;281(24):2305-15.
- 502 22. Bhattacharya J, Goldman D, Sood N. The link between public and private insurance and
503 HIV-related mortality. *Journal of Health Economics*. 2003;22(6):1105-22.
- 504 23. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors
505 with receipt of antiretroviral therapy. *American Journal of Public Health*. 2002;92(5):852-7.
- 506 24. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015
507 U.S. Transgender Survey 2016. Available from: <http://www.ustranssurvey.org/report/>.
- 508 25. Goldman DP, Bhattacharya J, McCaffrey DF, Duan N, Leibowitz AA, Joyce GF, et al.
509 Effect of insurance on mortality in an HIV-positive population in care. *Journal of the American
510 Statistical Association*. 2001;96(455):883-94.
- 511 26. Jasuja GK, de Groot A, Quinn EK, Ameli O, Hughto JM, Dunbar M, et al. Beyond
512 gender identity disorder diagnoses codes: An examination of additional methods to identify
513 transgender individuals in administrative databases. *Medical Care*. 2020;58(10):903-11.

- 514 27. Progovac AM, Cook BL, Mullin BO, McDowell A, Sanchez R MJ, Wang Y, et al.
515 Identifying gender minority patients' health and health care needs In administrative claims data.
516 Health Affairs. 2018;37(3):413-20.
- 517 28. Yee K, Lind BK, Downing J. Change in gender on record and transgender adults' mental
518 or behavioral health. American Journal of Preventive Medicine. 2021:1-9.
- 519 29. Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, et al. Ten-year trends in
520 antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS (London, England).
521 2017;31(12):1697.
- 522 30. Youn B, Shireman TI, Lee Y, Galárraga O, Wilson IB. Trends in medication adherence
523 in HIV patients in the US, 2001 to 2012: An observational cohort study. Journal of the
524 International AIDS Society. 2019;22(8):e25382.
- 525 31. Hughto J, Hughes L, Yee K, Downing J, Ellison J, Alpert A, et al. Improving data-driven
526 methods to identify and categorize transgender individuals by gender in insurance claims data.
527 LGBT Health. 2022.
- 528 32. RESDAC. Research Triangle Institute (RTI) Race Code: Research Data Assistance
529 Center & Centers Medicare and Medicaid Services; 2024 [Available from:
530 <https://resdac.org/cms-data/variables/research-triangle-institute-rti-race-code>].
- 531 33. CMS. Quality ID #340 (NQF 2079): HIV Medical Visit Frequency – National Quality
532 Strategy Domain: Efficiency and Cost Reduction
533 – Meaningful Measure Area: Management of Chronic Conditions: Centers for Medicare and
534 Medicaid Services, Quality Performance Project; 2020 [Available from:
535 [https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2020_Measure_340_MIPSCQM_v4.1.pdf)
536 [Measures/2020_Measure_340_MIPSCQM_v4.1.pdf](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2020_Measure_340_MIPSCQM_v4.1.pdf)].
- 537 34. CMS. Measure #205 (NQF 0409): HIV/AIDS: Sexually Transmitted Disease Screening
538 for Chlamydia, Gonorrhea, and Syphilis – National Quality Strategy Domain: Effective Clinical
539 Care: Centers for Medicare and Medicaid Services, Quality Performance Project; 2017
540 [Available from: [https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_205_Registry.pdf)
541 [Registry-Measures/2017_Measure_205_Registry.pdf](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_205_Registry.pdf)].
- 542 35. PQA. PQA Adherence Measures: Pharmacy Quality Alliance; 2022 [Available from:
543 <https://www.pqaalliance.org/adherence-measures>].

- 544 36. PQA. PQA's Adherence to Antiretrovirals Quality Measure: Evaluation of HIV
545 Treatment Adherence, an Indicator of Quality Care Pharmacy Quality Alliance; 2019 [Available
546 from: https://www.pqaalliance.org/assets/Measures/PQA_HIV_Measure_Overview.pdf.
- 547 37. Henderson KC, Hindman J, Johnson SC, Valuck RJ, Kiser JJ. Assessing the effectiveness
548 of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV.
549 AIDS Patient Care and STDs. 2011;25(4):221-8.
- 550 38. Cooke CE, Lee HY, Xing S. Adherence to antiretroviral therapy in managed care
551 members in the United States: A retrospective claims analysis. J Manag Care Pharm.
552 2014;20(1):86-92.
- 553 39. Byrd KK, Hou JG, Hazen R, Kirkham H, Suzuki S, Clay PG, et al. Antiretroviral
554 adherence level necessary for HIV viral suppression using real-world data. Journal of Acquired
555 Immune Deficiency Syndromes (1999). 2019;82(3):245.
- 556 40. Li P, Prajapati G, Geng Z, Ladage VP, Arduino JM, Watson DL, et al. Antiretroviral
557 treatment gaps and adherence among people with HIV in the US Medicare program. AIDS and
558 Behavior. 2023:1-13.
- 559 41. Coleman E, Radix A, Bouman W, Brown G, De Vries A, Deutsch M, et al. Standards of
560 care for the health of transgender and gender diverse people, version 8. International Journal of
561 Transgender Health. 2022.
- 562 42. Blinded.
- 563 43. Baguso GN, Gay CL, Lee KA. Medication adherence among transgender women living
564 with HIV. AIDS Care. 2016;28(8):976-81.
- 565 44. Teti M, Bauerband L, Altman C. Adherence to antiretroviral therapy among transgender
566 and gender nonconforming people living with HIV: Findings from the 2015 US Trans Survey.
567 Transgender Health. 2019;4(1):262-9.
- 568 45. Sevelius JM, Saberi P, Johnson MO. Correlates of antiretroviral adherence and viral load
569 among transgender women living with HIV. AIDS Care. 2014;26(8):976-82.
- 570 46. Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper GW.
571 Characterizing the HIV prevention and care continua in a sample of transgender youth in the
572 U.S. AIDS and Behavior. 2017;21(12):3312-27.

- 573 47. Lacombe-Duncan A, Shokoohi M, Persad Y, Underhill A, Machouf N, Côté P, et al.
574 Characterizing HIV care among a clinical sample of transgender women living with HIV. *HIV*
575 *Medicine*. 2022;23(4):324-30.
- 576 48. Rosen JG, Malik M, Cooney EE, Wirtz AL, Yamanis T, Lujan M, et al. Antiretroviral
577 treatment interruptions among Black and Latina transgender women living with HIV:
578 Characterizing co-occurring, multilevel factors using the gender affirmation framework. *AIDS*
579 *and Behavior*. 2019;23:2588-99.
- 580 49. Chyten-Brennan J, Patel VV, Anastos K, Hanna DB. Brief report: Role of gender-
581 affirming hormonal care in HIV care continuum outcomes when comparing transgender women
582 with cisgender sexual minority men. *JAIDS Journal of Acquired Immune Deficiency*
583 *Syndromes*. 2022;91(3):255-60.
- 584 50. Koma W, Rae M, Ramaswamy A, Neuman T, Kates J, Published LD. Demographics,
585 insurance coverage, and access to care among transgender adults: Kaiser Family Foundation;
586 2020 [Available from: [https://www.kff.org/affordable-care-act/issue-brief/demographics-](https://www.kff.org/affordable-care-act/issue-brief/demographics-insurance-coverage-and-access-to-care-among-transgender-adults/)
587 [insurance-coverage-and-access-to-care-among-transgender-adults/](https://www.kff.org/affordable-care-act/issue-brief/demographics-insurance-coverage-and-access-to-care-among-transgender-adults/)].
- 588 51. Meyer IH, Brown TN, Herman JL, Reisner SL, Bockting WO. Demographic
589 characteristics and health status of transgender adults in select US regions: Behavioral Risk
590 Factor Surveillance System, 2014. *American Journal of Public Health*. 2017;107(4):582-9.
- 591 52. Blosnich JR, Cashy J, Gordon AJ, Shipherd JC, Kauth MR, Brown GR, et al. Using
592 clinician text notes in electronic medical record data to validate transgender-related diagnosis
593 codes. *Journal of the American Medical Informatics Association*. 2018;25(7):905-8.
- 594 53. Reisner SL, Hughto JM. Comparing the health of non-binary and binary transgender
595 adults in a statewide non-probability sample. *PLoS One*. 2019;14(8):e0221583.
- 596 54. Pharr JR. Health disparities among lesbian, gay, bisexual, transgender, and nonbinary
597 adults 50 years old and older in the United States. *LGBT Health*. 2021;8(7):473-85.
598

Table 1. Demographic characteristics of transgender and gender diverse (TGD) (n=1,678) and cisgender (n=10,681) Medicare beneficiaries with HIV overall and by gender subgroup, 2008-2017.

	TGD N=1,678						Cisgender N=10,681				Total N=12,359			
	TFN n=1,053		TMN N=169		Unclassified N=456		Male N=7,143		Female N=3,538		TGD N=1,678		Cisgender N=10,681	
	N	%	N	%	N	%	N	(%)	N	(%)	N	%	N	%
AGE GROUP														
18-24	76	7.2%	21	12.4%	49	10.7%	115	1.6%	200	5.7%	146	8.7%	315	2.9%
25-34	242	23.0%	49	29.0%	116	25.4%	588	8.2%	528	14.9%	407	24.3%	1116	10.4%
35-44	389	36.9%	56	33.1%	145	31.8%	1669	23.4%	718	20.3%	590	35.2%	2387	22.3%
45-54	244	23.2%	29	17.2%	95	20.8%	2294	32.1%	865	24.4%	368	21.9%	3159	29.6%
>=55	102	9.7%	14	8.3%	51	11.2%	2477	34.7%	1227	34.7%	167	10.0%	3704	34.7%
RACE OR ETHNICITY														
White, non-Hispanic	343	32.6%	76	45.0%	149	32.7%	3309	46.3%	1241	35.1%	568	33.8%	4550	42.6%
Black, non-Hispanic	534	50.7%	69	40.8%	228	50.0%	2562	35.9%	1654	46.7%	831	49.5%	4216	39.5%
Hispanic	151	14.3%	14	8.3%	55	12.1%	991	13.9%	523	14.8%	220	13.1%	1514	14.2%
Another race or ethnicity	25	2.4%	10	5.9%	24	5.3%	281	3.9%	120	3.4%	59	3.5%	401	3.8%
CENSUS REGION														
Northeast	214	20.3%	43	25.4%	99	21.7%	1581	22.1%	946	26.7%	356	21.2%	2527	23.7%
Midwest	177	16.8%	25	14.8%	68	14.9%	1044	14.6%	504	14.2%	270	16.1%	1548	14.5%
South	431	40.9%	56	33.1%	181	39.7%	3011	42.2%	1637	46.3%	668	39.8%	4648	43.5%
West	231	21.9%	45	26.6%	108	23.7%	1455	20.4%	412	11.6%	384	22.9%	1867	17.5%
Missing	0	0.0%	0	0.0%	0	0.0%	52	0.7%	39	1.1%	0	0.0%	91	0.9%

Note. Demographics were assessed at enrollment. TGD=Transgender and gender diverse. TFN= trans feminine and non-binary; TMN=trans masculine and non-binary; Unclassified=gender category could not be determined. Due to small cell sizes that cannot be reported according to our Medicare data use agreement, we combined Asian/Pacific Islander, American Indian/Alaska Native, and other race or ethnicity under the “Another race or ethnicity” category.




Fig 1. HIV Care Continuum engagement among TGD and cisgender Medicare beneficiaries overall and by gender. The predicted probability of each outcome for TGD (transgender and gender diverse) and cisgender Medicare beneficiaries (2008-2017 by gender: TFN = trans feminine and non-binary; TMN = trans masculine and non-binary; Unclassified = gender category could not be determined. ART = Antiretroviral. STI = Sexually Transmitted Infections.

Supplement Table 1. Unadjusted prevalence of HIV Care Engagement Outcomes among transgender and gender diverse (TGD) (n=1,678) and cisgender (n=10,681) Medicare beneficiaries with HIV, overall and by gender subgroup, 2008-2017.

	TGD						Cisgender				Total			
	TFN		TMN		Unclassified		Male		Female		TGD		Cisgender	
HIV Care Visits	N=625	%	N=78	%	N=232	%	N=3,719	%	N=1,747	%	N=935	%	N=5,466	%
2008	97	19.4%	12	19.4%	18	13.3%	524	16.9%	273	20.2%	127	18.2%	797	17.9%
2009	120	21.1%	15	18.5%	37	24.0%	578	16.9%	297	18.7%	172	21.4%	875	17.5%
2010	146	23.1%	11	12.8%	33	17.7%	668	17.7%	350	19.3%	190	21.0%	1018	18.2%
2011	153	21.8%	19	18.1%	47	21.8%	782	19.1%	382	19.0%	219	21.4%	1164	19.0%
2012	176	23.1%	17	14.2%	43	17.7%	848	19.2%	390	18.0%	236	21.0%	1238	18.8%
2013	213	26.7%	22	16.4%	67	24.0%	1035	22.1%	459	19.6%	302	24.9%	1494	21.3%
2014	220	28.2%	17	13.2%	64	21.8%	1111	23.4%	472	19.8%	301	25.0%	1583	22.2%
2015	216	28.0%	25	19.5%	77	25.6%	1223	25.0%	537	21.7%	318	26.5%	1760	23.9%
2016	242	30.7%	31	24.4%	72	22.2%	1399	27.5%	607	23.9%	345	27.8%	2006	26.3%
2017	222	29.6%	26	20.8%	87	26.0%	1386	26.6%	581	23.1%	335	27.7%	1967	25.4%
STI Screening	N=541	%	N=62	%	N=168	%	N=2,028	%	N=951	%	N=771	%	N=2,979	%
2008	63	12.6%	4	6.5%	14	10.4%	192	6.2%	88	6.5%	81	11.6%	280	6.3%
2009	87	15.3%	8	9.9%	15	9.7%	265	7.8%	128	8.1%	110	13.7%	393	7.9%
2010	96	15.2%	9	10.5%	16	8.6%	343	9.1%	149	8.2%	121	13.4%	492	8.8%
2011	134	19.1%	14	13.3%	25	11.6%	400	9.8%	190	9.4%	173	16.9%	590	9.7%
2012	173	22.7%	16	13.3%	35	14.4%	502	11.4%	177	8.2%	224	19.9%	679	10.3%
2013	196	24.5%	19	14.2%	41	14.7%	593	12.7%	220	9.4%	256	21.1%	813	11.6%
2014	187	24.0%	17	13.2%	38	12.9%	617	13.0%	241	10.1%	242	20.1%	858	12.0%
2015	202	26.2%	25	19.5%	52	17.3%	644	13.2%	259	10.5%	279	23.3%	903	12.3%
2016	203	25.7%	26	20.5%	71	21.9%	685	13.5%	247	9.7%	300	24.2%	932	12.2%
2017	194	25.9%	26	20.8%	72	21.5%	751	14.4%	274	10.9%	292	24.1%	1025	13.2%
Prescribed ART	N=879	%	N=89	%	N=365	%	N=4,838	%	N=1,759	%	N=1,333	%	N=6,597	%
2008	306	64.3%	22	37.9%	88	70.4%	1687	54.6%	514	38.0%	416	63.1%	2201	49.5%
2009	372	68.8%	27	35.5%	100	70.9%	1898	55.6%	588	37.1%	499	65.8%	2486	49.7%
2010	439	73.3%	27	34.6%	115	69.3%	2098	55.5%	683	37.7%	581	68.9%	2781	49.7%
2011	484	72.8%	39	40.2%	139	70.2%	2262	55.2%	739	36.7%	662	69.0%	3001	49.1%
2012	561	77.5%	44	39.3%	161	72.9%	2596	58.8%	867	40.0%	766	72.5%	3463	52.6%
2013	592	77.2%	49	39.2%	184	71.0%	2793	59.7%	944	40.4%	825	71.7%	3737	53.2%
2014	572	76.5%	52	43.0%	200	73.5%	2853	60.0%	991	41.6%	824	72.2%	3844	53.9%
2015	560	75.8%	54	45.0%	209	75.7%	2945	60.3%	1081	43.7%	823	72.5%	4026	54.7%
2016	591	77.9%	53	44.5%	224	75.9%	3213	63.1%	1149	45.2%	868	74.0%	4362	57.1%


2017	576	79.8%	62	53.4%	237	78.0%	3392	65.0%	1205	47.8%	875	76.6%	4597	59.4%
ART Persistence: 90%	N=576	%	N=47	%	N=208	%	N=3,237	%	N=1,059	%	N=831	%	N=4,296	%
2008	94	19.7%	5	8.6%	31	24.8%	619	24.0%	172	15.2%	130	19.7%	791	21.3%
2009	134	24.8%	10	13.2%	32	22.7%	814	28.6%	225	16.7%	176	23.2%	1,039	24.8%
2010	163	27.2%	12	15.4%	47	28.3%	917	28.9%	267	17.0%	222	26.3%	1,184	25.0%
2011	201	30.2%	9	9.3%	39	19.7%	977	28.0%	292	16.5%	249	25.9%	1,269	24.2%
2012	239	33.0%	14	12.5%	55	24.9%	1,155	30.3%	345	17.8%	308	29.1%	1,500	26.1%
2013	253	33.0%	22	17.6%	71	27.4%	1,288	31.5%	408	19.0%	346	30.1%	1,696	27.2%
2014	256	34.2%	20	16.5%	79	29.0%	1,341	32.3%	404	18.5%	355	31.1%	1,745	27.6%
2015	251	34.0%	25	20.8%	89	32.2%	1,384	32.9%	466	20.6%	365	32.2%	1,850	28.6%
2016	268	35.3%	21	17.6%	80	27.1%	1,524	34.4%	519	22.2%	369	31.5%	2,043	30.2%
2017	284	39.3%	28	24.1%	103	33.9%	1,663	36.9%	545	23.6%	415	36.3%	2,208	32.4%
ART Persistence: 95%	N=429	%	N=31	%	N=147	%	N=2,342	%	N=726	%	N=607	%	N=3,068	%
2008	48	10.1%	3	5.2%	14	11.2%	301	11.7%	82	7.3%	65	9.9%	383	10.3%
2009	74	13.7%	4	5.3%	17	12.1%	383	13.5%	111	8.2%	95	12.5%	494	11.8%
2010	84	14.0%	6	7.7%	24	14.5%	437	13.8%	140	8.9%	114	13.5%	577	12.2%
2011	99	14.9%	3	3.1%	19	9.6%	493	14.2%	137	7.7%	121	12.6%	630	12.0%
2012	124	17.1%	7	6.3%	21	9.5%	599	15.7%	171	8.8%	152	14.4%	770	13.4%
2013	120	15.6%	8	6.4%	37	14.3%	605	14.8%	183	8.5%	165	14.3%	788	12.7%
2014	117	15.6%	12	9.9%	42	15.4%	649	15.6%	197	9.0%	171	15.0%	846	13.4%
2015	132	17.9%	14	11.7%	36	13.0%	658	15.6%	235	10.4%	182	16.0%	893	13.8%
2016	143	18.8%	14	11.8%	43	14.6%	796	18.0%	270	11.6%	200	17.1%	1,066	15.8%
2017	142	19.7%	10	8.6%	48	15.8%	818	18.1%	242	10.5%	200	17.5%	1,060	15.6%

Note. The percentages reflect the row total for a given year. TGD= Transgender and gender diverse; TFN= trans feminine and non-binary; TMN = trans masculine and non-binary; Unclassified = gender category could not be determined. ART = Antiretroviral. STI= Sexually Transmitted Infections.


Supplement Table 2. Predicted probabilities of HIV Care Continuum engagement among transgender and gender diverse (TGD) (n=1,678) and cisgender (n=10,681) Medicare beneficiaries with HIV, overall and by gender subgroup, 2008-2017.

Gender	Estimate	SE	Lower	Upper
HIV Care Visits				
TFN	0.25	0.009	0.24	0.27
TMN	0.18	0.020	0.14	0.22
Unclassified	0.22	0.014	0.20	0.25
TGD	0.23	0.007	0.22	0.24
Cisgender	0.22	0.003	0.21	0.22
Cisgender Male	0.22	0.003	0.22	0.23
Cisgender Female	0.21	0.005	0.20	0.22
STI Screening				
TFN	0.22	0.009	0.21	0.24
TMN	0.14	0.019	0.10	0.18
Unclassified	0.15	0.012	0.13	0.17
TGD	0.12	0.003	0.11	0.12
Cisgender	0.09	0.003	0.09	0.10
Cisgender Male	0.16	0.006	0.15	0.17
Cisgender Female	0.11	0.002	0.11	0.12
Prescribed ART				
TFN	0.71	0.012	0.69	0.74
TMN	0.41	0.034	0.34	0.47
Unclassified	0.68	0.020	0.64	0.71
TGD	0.61	0.011	0.59	0.63
Cisgender	0.52	0.004	0.52	0.54
Cisgender Male	0.58	0.005	0.57	0.59
Cisgender Female	0.40	0.008	0.39	0.42
ART: 90% Persistence				
TFN	0.30	0.010	0.28	0.32
TMN	0.15	0.023	0.11	0.20
Unclassified	0.25	0.016	0.22	0.28
TGD	0.27	0.008	0.25	0.28
Cisgender	0.23	0.003	0.22	0.23
Cisgender Male	0.26	0.004	0.25	0.27
Cisgender Female	0.17	0.005	0.16	0.18
ART: 95% Persistence				
TFN	0.15	0.007	0.14	0.16
TMN	0.07	0.014	0.04	0.10
Unclassified	0.12	0.010	0.10	0.14
TGD	0.13	0.005	0.12	0.14
Cisgender	0.11	0.002	0.11	0.12
Cisgender Male	0.13	0.003	0.12	0.13
Cisgender Female	0.08	0.003	0.07	0.09

Note. TGD = Transgender and gender diverse; TFN = trans feminine and non-binary; TMN = trans masculine and non-binary; Unclassified = gender category could not be determined. SE= Standard Error. Lower and Upper = Lower and Upper 95% Confidence Intervals. STI = Sexually Transmitted Infection. ART = Antiretroviral medication.



Supplement Fig 1. Transgender and Gender Diverse (TGD) Medicare Beneficiaries with HIV, 2008-2017. Flow diagram of TGD sample. The following individuals were excluded: individuals under 18 and those who died or did not have continuous Fee-for-Service coverage for at least 6 months of the performance year, leaving a final analytic sample of N=10,681. IP=inpatient; OP=outpatient; LTC=long term care; ART=antiretroviral medication; ICD=International Classification of Diseases.



Supplement Figure 2: Cisgender Medicare Beneficiaries with HIV, 2008-2017. Flow diagram of TGD sample. The following individuals were excluded: individuals under 18 and those who died or did not have continuous Fee-for-Service coverage for at least 6 months of the performance year, leaving a final analytic sample of N=10,681. IP=inpatient; OP=outpatient; LTC=long term care; ART=antiretroviral medication; ICD=International Classification of Diseases.